RZLT on Nasdaq

Rezolute, Inc.

American pharmaceutical preparations company based in Redwood City.

Price unavailable

Last updated Oct 18, 2026.

Overview

-$77.6MNet income, fiscal 2026²

Compare with another stock.

TickerRZLT on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersRedwood City, United States
Incorporated inNV³
Business address275 Shoreline Drive, Suite 500, Redwood City, Ca 94065³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-77.1%Return on equity²

Financial statements

Operating income⁴⁵⁶⁷⁸⁹²-$83.0M in 2026+220% since 2019

Net income⁴⁵⁶⁷⁸⁹²-$77.6M in 2026+155% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2026-06-30	2025-06-30
Research and development	$53.8M	$61.5M
General and administrative	$29.2M	$18.4M
Total operating expenses	$83.0M	$79.9M
Operating loss	-$83.0M	-$79.9M
Interest and other income, net	$5.4M	$5.5M
Net loss	-$77.6M	-$74.4M
Net unrealized gain (loss) on marketable debt securities	-$112.0K	$72.0K
Comprehensive loss	-$77.7M	-$74.3M
Net loss per common share - basic (in dollars per share)	-$0.75	-$0.98
Net loss per common share - diluted (in dollars per share)	-$0.75	-$0.98
Weighted average shares outstanding - basic (in shares)	103.9M shares	76.0M shares
Weighted average shares outstanding - diluted (in shares)	103.9M shares	76.0M shares

Total assets⁴⁵⁶⁷⁸⁹²$112.8M in 2026+821% since 2019

Total liabilities⁴⁵⁶⁷⁸⁹²$12.2M in 2026+16% since 2019

Shareholders’ equity⁵⁶⁷⁸⁹²$100.7M in 2026+5647% since 2019

Cash⁴⁵⁶⁷⁸⁹²$10.6M in 2026−8% since 2019

Long-term debt¹³⁵⁶$14.0M in 2021

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2026-06-30	2025-06-30	2024-06-30
Cash and cash equivalents	$10.6M	$94.1M
Investments in marketable debt securities	$97.2M	$73.8M
Prepaid expenses and other	$2.7M	$3.3M
Total current assets	$110.5M	$171.1M
Deposits and other	$1.5M	$2.9M
Right-of-use assets	$769.0K	$1.3M
Property and equipment, net	$41.0K	$72.0K
Total assets	$112.8M	$175.5M
Accounts payable	$5.0M	$5.8M
Accrued clinical and other	$3.7M	$3.2M
Compensation and benefits	$2.0M	$2.3M
Current portion of operating lease liabilities	$658.0K	$632.0K
Total current liabilities	$11.4M	$11.9M
Embedded derivative liability	$468.0K	$468.0K
Operating lease liabilities, net of current portion	$276.0K	$983.0K
Total liabilities	$12.2M	$13.4M
Common stock, $0.001 par value per share; 165,000,000 shares authorized; issued and outstanding 96,405,982 and 86,995,985 shares as of June 30, 2026 and 2025, respectively	$96.0K	$87.0K
Additional paid-in capital	$582.2M	$565.9M
Accumulated other comprehensive loss	-$119.0K	-$7.0K
Accumulated deficit	-$481.4M	-$403.9M
Total shareholders' equity	$100.7M	$162.1M	$121.0M
Total liabilities and shareholders' equity	$112.8M	$175.5M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	400.0K shares	400.0K shares
Preferred stock, shares, issued	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	165.0M shares	165.0M shares
Common stock, shares issued	96.4M shares	87.0M shares
Common stock, shares outstanding	96.4M shares	87.0M shares

Period ending	2026-06-30	2025-06-30	2024-06-30
Cash and cash equivalents	$10.6M	$94.1M
Investments in marketable debt securities	$97.2M	$73.8M
Prepaid expenses and other	$2.7M	$3.3M
Total current assets	$110.5M	$171.1M
Deposits and other	$1.5M	$2.9M
Right-of-use assets	$769.0K	$1.3M
Property and equipment, net	$41.0K	$72.0K
Total assets	$112.8M	$175.5M
Accounts payable	$5.0M	$5.8M
Accrued clinical and other	$3.7M	$3.2M
Compensation and benefits	$2.0M	$2.3M
Current portion of operating lease liabilities	$658.0K	$632.0K
Total current liabilities	$11.4M	$11.9M
Embedded derivative liability	$468.0K	$468.0K
Operating lease liabilities, net of current portion	$276.0K	$983.0K
Total liabilities	$12.2M	$13.4M
Common stock, $0.001 par value per share; 165,000,000 shares authorized; issued and outstanding 96,405,982 and 86,995,985 shares as of June 30, 2026 and 2025, respectively	$96.0K	$87.0K
Additional paid-in capital	$582.2M	$565.9M
Accumulated other comprehensive loss	-$119.0K	-$7.0K
Accumulated deficit	-$481.4M	-$403.9M
Total shareholders' equity	$100.7M	$162.1M	$121.0M
Total liabilities and shareholders' equity	$112.8M	$175.5M
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	400.0K shares	400.0K shares
Preferred stock, shares, issued	0 shares	0 shares
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	165.0M shares	165.0M shares
Common stock, shares issued	96.4M shares	87.0M shares
Common stock, shares outstanding	96.4M shares	87.0M shares

Cash from operations⁴⁵⁶⁷⁸⁹²-$64.6M in 2026+322% since 2019

Capital spending⁴⁸$153.0K in 2023+226% since 2019

Free cash flow⁴⁵⁸-$44.6M in 2023+191% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2026-06-30	2025-06-30
Net loss	-$77.6M	-$74.4M
Share-based compensation expense	$14.5M	$7.1M
Non-cash lease expense	$579.0K	$532.0K
Depreciation expense	$31.0K	$31.0K
Accretion of discounts and amortization of premiums on marketable debt securities, net	-$2.4M	-$2.4M
Prepaid expenses, deposits, and other assets	$1.5M	-$2.1M
Accounts payable	-$748.0K	$1.4M
Accrued liabilities	-$418.0K	$721.0K
Net cash used in operating activities	-$64.6M	-$69.1M
Purchase of marketable debt securities	-$178.2M	-$128.1M
Proceeds from maturities of marketable debt securities	$157.1M	$113.6M
Net cash used in investing activities	-$21.1M	-$14.5M
Proceeds from exercise of stock options	$2.3M	$893.0K
Payment of offering costs	-$35.0K	-$1.1M
Net cash provided by financing activities	$2.2M	$107.3M
Net change in cash and cash equivalents	-$83.5M	$23.7M
Cash paid for amounts included in the measurement of operating lease liabilities	$770.0K	$748.0K
Receivable from exercise of stock options	$25.0K	$503.0K
Payables for offering costs charged to additional paid-in capital		$35.0K

Compare Rezolute, Inc. with another company

Leadership

Who has led Rezolute, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

201520202025

Chief executive officerNevan C. Elam Feb 8, 2013 to now¹⁴
ChairHoyoung Huh Jan 18, 2017 to Jan 18, 2017¹⁵
PresidentNir Bar Sep 19, 2011 to Sep 6, 2012¹⁶
Chief financial officerDaron Evans Jan 25, 2024 to now¹⁷
Chief financial officerKeith A. Vendola May 17, 2018 to Sep 16, 2019¹⁸

Board members and other officers (16)

Chief Commercial OfficerSunil Ratilal Karnawat Aug 27, 2025 to now¹⁹
VP Finance & CAOSeline E. Miller Mar 7, 2019 to Mar 7, 2019²⁰
Chief Accounting OfficerMorgan Fields Jul 24, 2014 to Jan 13, 2017²¹
Chief Scientific OfficerSankaram Mantripragada Feb 8, 2013 to Sep 16, 2019²²
SecretaryGuy Turnowski Sep 6, 2012 to Sep 6, 2012²³
Board memberErik Harris Mar 26, 2025 to now²⁴
Board memberNerissa Kreher Mar 8, 2021 to now²⁵
Board memberWladimir Hogenhuis Mar 8, 2021 to now²⁶
Board memberPhilippe Fauchet Sep 16, 2020 to now²⁷
Board memberGil M. Labrucherie Nov 27, 2019 to now²⁸
Board memberDavid Welch Jun 29, 2015 to Mar 15, 2017²⁹
Board memberHoyoung Huh Feb 8, 2013 to May 2, 2014³⁰
Board memberNevan C. Elam Feb 8, 2013 to now¹⁴
Board memberNickolay Kukekov Feb 8, 2013 to Feb 8, 2013³¹
Board memberGuy Turnowski Sep 19, 2011 to Sep 6, 2012³²
Board memberNir Bar Sep 19, 2011 to Sep 6, 2012¹⁶

Former names

AntriaBio, Inc.Dec 11, 2012 to Dec 7, 2017³
FITS MY STYLE INCMay 17, 2011 to Jan 11, 2013³

Timeline

Feb 8, 2013New chief executive Nevan C. Elam becomes CEO¹⁴

Filings

274 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 74 major events, 94 insider forms, 39 large holders, 47 other. The latest 20:

Oct 14, 20268-K EDGAR
Oct 7, 2026PRE 14A EDGAR
Oct 5, 20268-K EDGAR
Sep 24, 202610-K EDGAR
Sep 24, 20268-K EDGAR
Sep 3, 20264 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 12, 2026SCHEDULE 13G EDGAR
Aug 12, 2026SCHEDULE 13G/A EDGAR
Jul 7, 20264 EDGAR
Jul 7, 20264 EDGAR
Jul 7, 20264 EDGAR
Jun 2, 20268-K EDGAR
May 15, 2026SCHEDULE 13G EDGAR
May 12, 202610-Q EDGAR
May 12, 20268-K EDGAR
May 11, 2026SCHEDULE 13G/A EDGAR
May 4, 20268-K EDGAR
Mar 31, 20264 EDGAR
Mar 26, 2026SCHEDULE 13G/A EDGAR

The 274 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 39 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Federated Hermes, Inc.	12,990,659	$67.6M	0.1%	No change
Ra Capital Management, L.P.	9,445,039	$49.1M	0.4%	+265,039
BlackRock, Inc.	7,718,291	$40.1M	0.0%	+1,404,788
Opaleye Management Inc.	6,300,000	$32.8M	3.0%	No change
Balyasny Asset Management L.P.	4,662,039	$24.2M	0.0%	−386,382
Vanguard Capital Management LLC	3,835,827	$19.9M	0.0%	+313,747
Siren, L.L.C.	3,328,287	$17.3M	0.4%	No change
Jacobs Levy Equity Management, Inc	2,561,654	$13.3M	0.0%	+2,341,247
Jennison Associates LLC	2,459,308	$12.8M	0.0%	−979,573
Geode Capital Management, LLC	2,170,154	$11.3M	0.0%	+205,795
State Street Corp	1,850,128	$9.6M	0.0%	+78,287
D. E. Shaw & Co., Inc.	1,839,357	$9.6M	0.0%	+73,377
Morgan Stanley	1,618,783	$8.4M	0.0%	−1,128,888
Vanguard Portfolio Management LLC	1,380,746	$7.2M	0.0%	−1,601,019
Goldman Sachs Group Inc	1,316,782	$6.8M	0.0%	+714,486
Nuveen, LLC	1,295,209	$6.7M	0.0%	+1,197,523
Kennedy Capital Management LLC	1,221,678	$6.4M	0.1%	−14,420
Blackstone Inc.	1,082,927	$5.6M	0.0%	New
Aqr Capital Management LLC	1,007,962	$5.2M	0.0%	+211,266
Affinity Asset Advisors, LLC	1,000,000	$5.2M	0.3%	−547,641
Great Point Partners LLC	951,809	$4.9M	1.2%	No change
Ikarian Capital, LLC	935,012	$4.9M	0.8%	+918,533
Dimensional Fund Advisors LP	890,733	$4.6M	0.0%	+360,504
22nw, LP	820,653	$4.3M	4.1%	No change
Velan Capital Investment Management LP	750,000	$3.9M	2.4%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARRezolute, Inc. filings on SEC EDGAR
2
SEC EDGARRezolute, Inc. 10-K for fiscal 2026
3
SEC EDGARRezolute, Inc. filings on SEC EDGAR
4
SEC EDGARRezolute, Inc. 10-K for fiscal 2019
5
SEC EDGARRezolute, Inc. 10-K for fiscal 2020
6
SEC EDGARRezolute, Inc. 10-K for fiscal 2021
7
SEC EDGARRezolute, Inc. 10-K for fiscal 2022
8
SEC EDGARRezolute, Inc. 10-K for fiscal 2023
9
SEC EDGARRezolute, Inc. 10-K for fiscal 2024
10
SEC EDGARRezolute, Inc. 10-Q for fiscal 2025
11
SEC EDGARRezolute, Inc. 10-Q for fiscal 2025
12
SEC EDGARRezolute, Inc. 10-Q for fiscal 2026
13
SEC EDGARRezolute, Inc. 10-K for fiscal 2019
14
SEC EDGARNevan C. Elam, Chief executive officer
15
SEC EDGARHoyoung Huh, Chair
16
SEC EDGARNir Bar, President
17
SEC EDGARDaron Evans, Chief financial officer
18
SEC EDGARKeith A. Vendola, Chief financial officer
19
SEC EDGARSunil Ratilal Karnawat, Chief Commercial Officer
20
SEC EDGARSeline E. Miller, VP Finance & CAO
21
SEC EDGARMorgan Fields, Chief Accounting Officer
22
SEC EDGARSankaram Mantripragada, Chief Scientific Officer
23
SEC EDGARGuy Turnowski, Secretary
24
SEC EDGARErik Harris, Board member
25
SEC EDGARNerissa Kreher, Board member
26
SEC EDGARWladimir Hogenhuis, Board member
27
SEC EDGARPhilippe Fauchet, Board member
28
SEC EDGARGil M. Labrucherie, Board member
29
SEC EDGARDavid Welch, Board member
30
SEC EDGARHoyoung Huh, Board member
31
SEC EDGARNickolay Kukekov, Board member
32
SEC EDGARGuy Turnowski, Board member